Fusion Pharmaceuticals (NASDAQ:FUSN) Stock Price Up 6.3%

Fusion Pharmaceuticals Inc. (NASDAQ:FUSNGet Free Report) rose 6.3% during trading on Tuesday . The company traded as high as $9.66 and last traded at $9.58. Approximately 769,609 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,388,862 shares. The stock had previously closed at $9.01.

Analyst Ratings Changes

FUSN has been the topic of a number of research reports. Oppenheimer upped their price objective on Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an “outperform” rating in a report on Friday, January 5th. Bloom Burton reaffirmed a “buy” rating on shares of Fusion Pharmaceuticals in a report on Friday, January 5th. Raymond James upped their price objective on Fusion Pharmaceuticals from $15.00 to $16.00 and gave the company a “strong-buy” rating in a report on Friday, January 5th. William Blair reissued an “outperform” rating on shares of Fusion Pharmaceuticals in a report on Friday, January 5th. Finally, Royal Bank of Canada initiated coverage on Fusion Pharmaceuticals in a report on Wednesday, December 20th. They set an “outperform” rating and a $12.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.17.

Read Our Latest Analysis on FUSN

Fusion Pharmaceuticals Trading Up 1.5 %

The company has a current ratio of 11.63, a quick ratio of 11.63 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average price of $6.44 and a 200-day moving average price of $4.50.

Fusion Pharmaceuticals (NASDAQ:FUSNGet Free Report) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.15. The business had revenue of $2.01 million for the quarter, compared to analyst estimates of $0.41 million. Fusion Pharmaceuticals had a negative return on equity of 48.42% and a negative net margin of 4,136.55%. Equities analysts forecast that Fusion Pharmaceuticals Inc. will post -1.44 earnings per share for the current year.

Institutional Trading of Fusion Pharmaceuticals

Large investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in Fusion Pharmaceuticals in the second quarter valued at about $29,000. Schonfeld Strategic Advisors LLC acquired a new stake in Fusion Pharmaceuticals in the first quarter valued at about $49,000. Renaissance Technologies LLC bought a new position in Fusion Pharmaceuticals in the third quarter valued at about $51,000. Citadel Advisors LLC bought a new position in Fusion Pharmaceuticals in the third quarter valued at about $86,000. Finally, Forefront Analytics LLC raised its position in Fusion Pharmaceuticals by 67.8% in the third quarter. Forefront Analytics LLC now owns 33,685 shares of the company’s stock valued at $88,000 after purchasing an additional 13,610 shares during the last quarter. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Company Profile

(Get Free Report)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Featured Articles

Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.